Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France

Affiliation auteurs!!!! Error affiliation !!!!
TitreEfficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France
Type de publicationJournal Article
Year of Publication2017
AuteursAyrignac X., Collongues N., De Seze J., Vermersch P., Brassat D., Biotti D., Carra-Dalliere C., Charif M., Vukusic S., Durand-Dubief F., Edan G., Lepage E., Deburghgraeve V., Maillart E., Papeix C., Alla P., Berger E., Bourre B., Casez O., Pittion S., Debouverie M., Derache N., Defer G., Gout O., Deschamps R., Tourbah A., Zagnoli F., Ruet A., Ouallet J.C, Brochet B., Manchon E., Moreau T., Fromont A., Clavelou P., Guennoc A-M., Camdessanche J.P, Carpentier A., Coman I., Audoin B., Pelletier J., Magy L., Wiertlewski S., Laplaud D., Ciron J., de Broucker T., C. Frenay L, Cohen M., Labauge P., Plaques CFrancophon, Plaques SFrancophon, OFSEP
JournalMULTIPLE SCLEROSIS JOURNAL
Volume23
Pagination604-605
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN1352-4585